Beyond LDL-C - The importance of raising HDL-C

Current Medical Research and Opinion

Volumn 18, Issue 1, 2002, Pages 36-44

  Wierzbicki, Anthony S ^a   Mikhailidis, Dimitri P ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Coronary heart disease; Dyslipidaemia; High density lipoprotein cholesterol; Lipid modifying drugs

Indexed keywords

ANTILIPEMIC AGENT; ATORVASTATIN; BEZAFIBRATE; CERIVASTATIN; CHOLESTEROL; EZETIMIBE; FIBRIC ACID DERIVATIVE; FLUINDOSTATIN; GEMFIBROZIL; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MEVINOLIN; NICOTINIC ACID; PLACEBO; PRAVASTATIN; RESIN; ROSUVASTATIN; SIMVASTATIN; TRIACYLGLYCEROL;

ARTICLE; ATHEROSCLEROSIS; CARDIOVASCULAR RISK; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL TRANSPORT; CLINICAL TRIAL; CORRELATION ANALYSIS; DRUG EFFECT; DRUG EFFICACY; DRUG TOLERABILITY; DYSLIPIDEMIA; FLUSHING; HEART INFARCTION; HUMAN; ISCHEMIC HEART DISEASE; LIVER TOXICITY; MYALGIA; PRACTICE GUIDELINE; PREDICTION; RHABDOMYOLYSIS; RISK BENEFIT ANALYSIS; TREATMENT OUTCOME; TRIACYLGLYCEROL BLOOD LEVEL; VASCULAR ENDOTHELIUM;

ANTILIPEMIC AGENTS; ARTERIOSCLEROSIS; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY DISEASE; GEMFIBROZIL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIPIDS; RISK FACTORS;

EID: 0036208934     PISSN: 03007995     EISSN: None     Source Type: Journal    
DOI: 10.1185/030079902125000165     Document Type: Article

References (84)

1. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The Scandinavian Simvastatin Survival Study (4S)
2. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels
3. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels
4. Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels. Results of AFCAPS/TexCAPS
5. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia
6. Prevention of coronary heart disease in clinical practice. Recommendations of the second joint task force of European and other societies on coronary prevention
7. Joint British recommendations on prevention of coronary heart disease in clinical practice
8. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)
9. Raising low levels of high-density lipoprotein cholesterol is an important target of therapy
10. Treating lipids in cardiovascular disease: New directions
11. Second report of the Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults. (Adult Treatment Panel II)
12. Distribution of lipids in 8,500 men with coronary artery disease
13. Lipoprotein cholesterol, apolipoprotein A-1 and B and lipoprotein (a) abnormalities in men with premature coronary artery disease
14. Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia
15. Triglycerides and coronary heart disease: Implications of recent clinical trials
16. Importance of HDL cholesterol levels and the total/HDL cholesterol ratio as a risk factor for coronary heart disease in molecularly defined heterozygous familial hypercholesterolaemia
17. George Lyman Duff memorial lecture. Atherogenesis in diabetes
18. Treating dyslipidaemia in non-insulin-dependent diabetes mellitus - A special reference to statins
19. Atherogenic dyslipidemia, and the metabolic syndrome
20. Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham study
21. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction. The Framingham study
22. Lipoprotein receptors in the liver: Control signals for plasma cholesterol traffic
23. Changing concepts of atherogenesis
24. The role of plaque rupture and thrombosis in coronary artery disease
25. Coronary atherosclerotic wall thickening and vascular reactivity in humans. Elevated high-density lipoprotein levels ameliorate abnormal vasoconstriction in early atherosclerosis
26. Oxidized lipoproteins inhibit endothelium-dependent vasodilation. Effects of pressure and high-density lipoprotein
27. High-density lipoproteins and atherosclerosis
28. The role of high-density lipoprotein and lipid-soluble antioxidant vitamins in inhibiting low-density lipoprotein oxidation
29. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM Experience)
30. Isolated low HDL cholesterol as a risk factor for coronary heart disease mortality. A 21-year follow-up of 8000 men
31. High-density lipoprotein cholesterol and cardiovascular disease. Four prospective American studies
32. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein AI
33. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice
34. Human apolipoprotein A-I gene expression increases high density lipoprotein and suppresses atherosclerosis in the apolipoprotein E-deficient mouse
35. Regression of atherosclerotic lesions by high density lipoprotein plasma fraction in the cholesterol-fed rabbit
36. High density lipoproteins and coronary heart disease
37. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol
38. Drug treatment of lipid disorders
39. Current, new and future treatments in dyslipidaemia and atherosclerosis
40. Efficacy and safety of an extended-release niacin (Niaspan): A long-term study
41. Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia
42. The benefits of niacin in atherosclerosis
43. Evaluating niacin in its various forms
44. Helsinki Heart Study: Primary-prevention trial with gemfibrozil in middle-aged men with dyslipidaemia. Safety of treatment, changes in risk factors, and incidence of coronary heart disease
45. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: The Bezafibrate Infarction Prevention (BIP) study
46. Veterans Affairs High-density Lipoprotein Intervention trial. Relation of gemfibrozil treatment and lipid levels with major coronary events: VA-HIT: A randomised controlled trial
47. Are high density lipoprotein (HDL) and triglyceride levels relevant in stroke prevention?
48. Are high-density lipoprotein and triglyceride levels important in secondary prevention - Impressions from the BIP and VA-HIT trials
49. Current perspectives on statins
50. Influence of low HDL and elevated TG on CHD events and response to simvastatin therapy in 4S
51. Do total and high density lipoprotein cholesterol and triglycerides act independently in the prediction of ischemic heart disease?: Ten-year follow-up of Caerphilly and Speedwell cohorts
52. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: The Prospective Pravastatin Pooling Project
53. Relation between baseline and on-treatment lipid parameters and first acute major coronary events in the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS)
54. HDL-cholesterol and the treatment of coronary heart disease: Contrasting effects of atorvastatin and simvastatin
55. Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin and fluvastatin in patients with hypercholesterolemia (the CURVES Study)
56. Treating patients with documented atherosclerosis to National Cholesterol Education Program-recommended low-densitylipoprotein cholesterol goals with atorvastatin, fluvastatin, lovastatin and simvastatin
57. Effects of high doses of simvastatin and atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I
58. Comparison of effects of simvastatin versus atorvastatin on high-density lipoprotein cholesterol and apolipoprotein A-I levels
59. Pleiotropic effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors
60. More on the effect of atorvastatin on plasma fibrinogen levels in primary hypercholesterolaemia
61. Drug treatment of combined hyperlipidemia
62. Treating mixed dyslipidemias: Why and how
63. Effects of fluvastatin and bezafibrate combination on plasma fibrinogen, T-plasminogen activator inhibitor and C reactive protein levels in coronary artery disease patients with mixed hyperlipidaemia (FACT study). Fluvastatin alone and in combination treatment
64. Statin + fibrate combination therapy: Fluvastatin with bezafibrate or ciprofibrate in high risk patients with vascular disease
65. Effects of Bezafibrate on insulin sensitivity and insulin secretion in nonobese Japanese type 2 diabetic patients
66. Effects of simvastatin and atorvastatin administration on insulin resistance and respiratory quotient in aged dyslipidemic noninsulin dependent diabetic patients
67. Effect of the HMGCoA reductase inhibitors on blood pressure in patients with essential hypertension and primary hypercholesterolemia
68. Bezafibrate reduces heart rate and blood pressure in patients with hypertriglyceridemia
69. Fibrates and statins in the treatment of hyperlipidaemia: An appraisal of their efficacy and safety
70. Statin-fibrate combination therapy
71. Withdrawal of cerivastatin from the world market
72. New combination niacin/statin formulation shows pronounced effects on major lipoproteins and is well tolerated
73. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461
74. Comparison of the activity and disposition of the novel cholesterol absorption inhibitor, SCH58235, and its glucuronide, SCH60663
75. Ezetimibe: A selective inhibitor of cholesterol absorption
76. Results of phase I/II clinical trials with ezetimibe, a novel selective cholesterol absorption inhibitor
77. Pharmacodynamic interaction between the new selective cholesterol absorption inhibitor ezetimibe and simvastatin
78. PIII-16 SCH 58235 does not affect the pharmacokinetics of simvastatin
79. Pharmacodynamic interaction between fenofibrate and the cholesterol absorption inhibitor ezetimibe
80. Long-term efficacy and safety of rosuvastatin: Results of a 52-week comparator-controlled trial versus pravastatin and simvastatin
81. Effect of rosuvastatin on low-density lipoprotein cholesterol in patients with hypercholesterolemia
82. Long-term efficacy and safety of rosuvastatin: Results of a 52-week comparator-controlled trial versus atorvastatin
83. Treatment of hypertriglyceridemic patients with rosuvastatin
84. Rosuvastatin (20, 40 and 80mg) reduces LDL-C, raises HDL-C and achieves treatment goals more effectively than atorvastatin (20, 40 and 80 mg) in patients with heterozygous familial hypercholesterolaemia